From Yahoo Finance: 2025-05-26 09:14:00

Analysts at Stifel reaffirmed their Buy rating and $48 price target for Bicara Therapeutics Inc. (NASDAQ: BCAX) after promising ASCO data for HPV-negative patients. The data showed an improved CR rate of 21%, 12-month duration of response, and OS of 60/61%. Merus, a market rival, also presented impressive data. Stifel advises investors to buy BCAX stock on price weakness and wait for more thorough information at the next ASCO meetings.

Read more: Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients